Page last updated: 2024-09-04

tariquidar and 5-hydroxy-3,3',4',7-tetramethoxyflavone

tariquidar has been researched along with 5-hydroxy-3,3',4',7-tetramethoxyflavone in 1 studies

Compound Research Comparison

Studies
(tariquidar)
Trials
(tariquidar)
Recent Studies (post-2010)
(tariquidar)
Studies
(5-hydroxy-3,3',4',7-tetramethoxyflavone)
Trials
(5-hydroxy-3,3',4',7-tetramethoxyflavone)
Recent Studies (post-2010) (5-hydroxy-3,3',4',7-tetramethoxyflavone)
2101613821013

Protein Interaction Comparison

ProteinTaxonomytariquidar (IC50)5-hydroxy-3,3',4',7-tetramethoxyflavone (IC50)
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.6

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bönisch, H; Haenisch, B; Mayer, R; Müller, CE; Müller, H; Pajeva, IK; Pick, A; Weigt, M; Wiese, M1

Other Studies

1 other study(ies) available for tariquidar and 5-hydroxy-3,3',4',7-tetramethoxyflavone

ArticleYear
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
    Bioorganic & medicinal chemistry, 2011, Mar-15, Volume: 19, Issue:6

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Hydrogen Bonding; Models, Molecular; Neoplasm Proteins; Quantitative Structure-Activity Relationship

2011